Importer of Controlled Substances Application: Sharp Clinical Services, LLC, 10730-10731 [2025-03060]
Download as PDF
<![CDATA[
10730
Federal Register / Vol. 90, No. 37 / Wednesday, February 26, 2025 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1440]
Certain Motorized Self-Balancing
Vehicles; Notice of Institution of
Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
January 3, 2025, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Razor USA LLC of Cerritos,
California and Shane Chen of Camas,
Washington. An amended complaint
was filed on January 21, 2025. The
complaint, as amended, alleges
violations of section 337 based upon the
importation into the United States, the
sale for importation, and the sale within
the United States after importation of
certain motorized self-balancing
vehicles by reason of the infringement
of certain claims of U.S. Patent No.
RE46,964 (‘‘the ’964 patent’’), U.S.
Patent No. RE49,608 (‘‘the ’608 patent’’),
and U.S. Patent No. D739,906 (‘‘the ’906
patent’’). The complaint further alleges
that an industry in the United States
exists or is in the process of being
established as required by the
applicable Federal Statute. The
complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Susan Orndoff, Office of Docket
Services, U.S. International Trade
Commission, telephone (202) 205–1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
khammond on DSK9W7S144PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:26 Feb 25, 2025
Jkt 265001
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2024).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
February 20, 2025, Ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
10–17 of the ’964 patent; claims 10–13
of the ’608 patent and claim 1 of the
’906 patent, and whether an industry in
the United States exists or is in the
process of being established as required
by subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘motorized twowheeled self-balancing vehicles without
handlebars’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are:
Razor USA LLC, 12723 166th St.,
Cerritos, California 90703
Shane Chen, 1821 NW 8th Ave., Camas,
Washington 98607
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Golabs Inc. d/b/a Gotrax, 2201 Luna
Road, Carrollton, Texas 75006
Dongguan Saibotan Nengyuan Keji Co.,
Ltd., d/b/a ‘‘Gyroor US’’, No. 1 Feida
Rd. Building A, 2F, Zhangyang
District, Zhangmatou Town,
Guangdong, China 523637
Gyroor Technology (CHINA) Co., Ltd.,
d/b/a Gyroor, No. 1800112, Dafu
Industrial Area, Guanlan Town,
Longhua District, Shenzhen City,
Guangdong, China 51800
Shenzhen Chitado Technology Co., Ltd.,
d/b/a Gyroor, Floor 901, 902, 11, 12,
13, Building 13, No., 6, Xincheng
Avenue, Guangpei Community,
Guanlan Town, Longhua District,
Shenzhen City, Guangdong, China
51800
PO 00000
Frm 00021
Fmt 4703
Sfmt 4703
Unicorn Network, LLC. d/b/a Sisigad,
c/o A Registered Agent, Inc., 8 The
Green, Ste. A, Dover, Delaware 19901
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge. The Office of
Unfair Import Investigations will not
participate as a party in this
investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainants of
the complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: February 20, 2025.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2025–03080 Filed 2–25–25; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1502]
Importer of Controlled Substances
Application: Sharp Clinical Services,
LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
E:\FR\FM\26FEN1.SGM
26FEN1
10731
Federal Register / Vol. 90, No. 37 / Wednesday, February 26, 2025 / Notices
Sharp Clinical Services, LLC
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 28, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 28, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
SUMMARY:
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on January 7, 2025, Sharp
Clinical Services, LLC, 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020–
8024, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Gamma Hydroxybutyric Acid ...........................................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Psilocybin .........................................................................................................................................................................
The company plans to import the
listed controlled substances for
distribution and clinical trials. No other
activities for these drug codes are
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025–03060 Filed 2–25–25; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1503]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
Drug Enforcement
Administration, Justice.
khammond on DSK9W7S144PROD with NOTICES
AGENCY:
ACTION:
Notice of application.
Catalent Pharma Solutions,
LLC has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before March 28, 2025. Such
persons may also file a written request
for a hearing on the application on or
before March 28, 2025.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
SUMMARY:
In
accordance with 21 CFR 1301.34(a), this
is notice that on November 19, 2024,
Catalent Pharma Solutions, LLC, 3031
Red Lion Road, Philadelphia,
Pennsylvania 19114–1123, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Drug code
Ibogaine ...........................................................................................................................................................................
VerDate Sep<11>2014
18:26 Feb 25, 2025
Jkt 265001
research, and analytical activities. No
other activity for this drug code is
authorized for this registration.
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
I
I
I
I
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
Controlled substance
The company plans to import the
listed controlled substance as finished
dosage unit products for clinical trials,
2010
7405
7431
7437
Schedule
7260
Schedule
I
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 90, Number 37 (Wednesday, February 26, 2025)]
[Notices]
[Pages 10730-10731]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-03060]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1502]
Importer of Controlled Substances Application: Sharp Clinical
Services, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
[[Page 10731]]
SUMMARY: Sharp Clinical Services, LLC has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
March 28, 2025. Such persons may also file a written request for a
hearing on the application on or before March 28, 2025.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on January 7, 2025, Sharp Clinical Services, LLC, 2400
Baglyos Circle, Bethlehem, Pennsylvania 18020-8024, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid.......... 2010 I
3,4-Methylenedioxymethamphetamine.. 7405 I
5-Methoxy-N-N-dimethyltryptamine... 7431 I
Psilocybin......................... 7437 I
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
distribution and clinical trials. No other activities for these drug
codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Matthew Strait,
Deputy Assistant Administrator.
[FR Doc. 2025-03060 Filed 2-25-25; 8:45 am]
BILLING CODE P
